SEP 26, 2016 10:51 AM PDT

Circadian Rhythm Gene Can Influence Breast Cancer Progression

Everyone knows sleep is important. Getting a good night’s sleep resets your brain, allows for efficient cell repair and aids in effective digestion. Interruptions in sleep/wake cycles, otherwise known as the circadian rhythm, have long been thought to contribute to cancer progression due to changes at the cell and tissue level.
 
Scientists at the National Cancer Institute have recently discovered that one of the circadian rhythm genes can specifically affect breast cancer metastasis. Breast cancer is one of the most common diagnoses in women in the United States, and breast cancer metastasis is the second leading cause of death in women. It is commonly known that the primary tumor is not what causes the high mortality rates in cancer; it is the metastasis of that tumor to other body parts. Metastasis can be hard to contain, and depending on the tumor type, might not have targeted therapies to treat.
Sections of myometrial muscle infiltrated by metastatic carcinoma. (Cesar A. Moran, CancerNetwork)
To complicate things even further, there are several different subtypes of malignancy that can affect tumor progression and treatment options. Two subtypes of breast cancer, ER+ (estrogen receptor-positive) and HER+ (human epidermal growth factor-positive), have targeted therapies specifically developed to these types of tumors even after they have disseminated throughout the body. These treatments target the tumor cells directly and negate the need for general therapies such as chemotherapy.

However, ER- and HER- tumor types do not respond well to these therapies and have a higher chance of metastasis and poor survival prognosis. A better understanding of the biology and genetics behind these ER- and HER- tumors would provide the basis for new targeted therapies and clinical treatments to improve the outcome of diagnosis and malignancy in these patients.
 
Studying crosses of genetically engineered mice with highly metastatic mammary tumors with those containing low frequency metastatic tumors provided gene signatures consistent with the ER- cancer subtype and led to the identification of Arntl2, a known circadian rhythm gene, as a metastatic susceptibility gene. Kent Hunter, one of the primary authors of the study and Senior Investigator at NCI, notes that this association suggests circadian rhythm plays a role in both the cause and progression of this very aggressive form of breast cancer.
Identification of the circadian rhythm Arntl2 gene and its relationship to cancer metastases (Siracusa LD, Bussard KM; 2016)
Based on mapping data from the cross, researchers genotyped an area that highlighted the Arntl2 gene as a primary cause for progressive metastasis in the mice and related cell lines. Further knockout experiments and association-based patient cohort studies were done to validate the Arntl2 gene as a causative gene to metastatic-specific cancer progression in the ER- subtype.

This study, published in PLOS Genetics, sheds light on metastasis and the many factors that enable a primary tumor to spread. Metastasis is a complicated process influenced by many factors, such as obtaining invasive and migratory abilities, gaining entry into the lymphatic system, and colonization of cells in a new environment. Given the different factors that go into cancer progression, it has become evident that there are several outside influencers and biological processes that can positively or negatively affect tumor progression.

Circadian rhythm disruption has been indicated in previous studies to increase breast cancer risk and survival rates based on epidemiological and gene expression studies. However, there have not been any causal effects shown until now. Hunter and team were able to prove that Arntl2 has a direct effect on the metastasis of ER- breast cancer. These findings provide a genetic basis for inherited susceptibility of cancer metastasis and emphasize the potential of incorporating behavioral adjustments such as more sleep and sustained sleep/wake cycles into cancer treatment.

Sources: PLOS Genetics, NCI, Reuters, Arntl2 Image
About the Author
  • I love all things science and am passionate about bringing science to the public through writing. With an M.S. in Genetics and experience in cancer research, marketing and technical writing, it is a pleasure to share the latest trends and findings in science on LabRoots.
You May Also Like
AUG 07, 2018
Cancer
AUG 07, 2018
Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association
DNA methylation patterns in renal cell carcinoma (RCC) have a strong association with myelodysplastic syndrome DNA hypermethylation later in life....
AUG 13, 2018
Videos
AUG 13, 2018
What does sunscreen look like with a UV camera?
  Have you ever wondered if there’s really a difference between SPF 30 and SPF 50? You’re not the only one. YouTuber Physics Girl set out...
AUG 15, 2018
Cancer
AUG 15, 2018
Cancer Control Headway in The Last 20 Years
Learning from history and what changes have been made will continue to help drive cancer controls for the future....
SEP 04, 2018
Cancer
SEP 04, 2018
Metal beads that could help reduce chemotherapy side effects in brain tumor
Brain tumors are one of the most challenging types of cancers to treat. Only 1 in 7 patients will survive the disease, and those survivors will usually suffer from lots of side effects becaus...
OCT 25, 2018
Health & Medicine
OCT 25, 2018
Sedentary Lifestyle More Deadly Than Smoking
A number of recent studies have found that first cardiovascular associations with regular high-intensity exercise. These studies......
NOV 14, 2018
Immunology
NOV 14, 2018
Rapid Tumor Targeting
Researchers at the University of California Irvine have developed a technology that will rapidly identify and target T cell receptors for tumor specific antigens...
Loading Comments...